Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode?

Monica McNeil

2017-11-24 08:41:00 Fri ET

Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode? As its prices skyrocket, bankers, pundits, and investors increasingly take sides. In accordance with Warren Buffett's intrinsic value philosophy, Bitcoin should not be viewed as a valuable asset because Bitcoin cannot yield future cash flows. Further, several bankers and experts such as Brian Moynihan (Bank of America CEO), Jamie Dimon (JPMorgan Chase CEO), Bill Dudley (New York Fed CEO), and Joseph Stiglitz (Nobel Laureate) emphasize that Bitcoin cannot be a stable store of value in light of its volatile price movements and technical impediments for Bitcoin to be a long-term viable legal tender. Nobel Laureate Robert Shiller regards Bitcoin as the modern epitome of a speculative asset bubble.

In contrast to this rather pessimistic view, many other proponents suggest that Bitcoin can serve as an alternative virtual currency in addition to legal tender in the current global payments system (especially for many emerging economies with weak legal rules, institutions, and unstable currencies). These proponents include Christine Lagarde (IMF Executive Director), Mark Cuban (VC billionaire), Peter Thiel (PayPal co-founder and VC billionaire), Bill Gates (Microsoft founder and philanthropist), Eric Schmidt (Alphabet chairman), Richard Branson (Virgin Group founder), Mark Carney (Governor of Bank of England), and so forth.

Time will tell whether Bitcoin will become a successful cryptocurrency!!

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The Chinese central bank has to circumvent offshore imports-driven inflation due to Renminbi currency misalignment.

Amy Hamilton

2019-07-07 18:36:00 Sunday ET

The Chinese central bank has to circumvent offshore imports-driven inflation due to Renminbi currency misalignment.

The Chinese central bank has to circumvent offshore imports-driven inflation due to Renminbi currency misalignment. Even though China keeps substantial fore

+See More

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Becky Berkman

2019-08-09 18:35:00 Friday ET

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups; whereas, the government should now reassert itself in terms o

+See More

AYA free finbuzz podcast channel on YouTube March 2019

Andy Yeh Alpha

2019-03-31 11:40:00 Sunday ET

AYA free finbuzz podcast channel on YouTube March 2019

AYA Analytica free finbuzz podcast channel on YouTube March 2019 In this podcast, we discuss several topical issues as of March 2019: (1) Sargent-Wallac

+See More

Netflix raises its prices by 13% to 18% for U.S. subscribers.

Chanel Holden

2019-01-25 13:34:00 Friday ET

Netflix raises its prices by 13% to 18% for U.S. subscribers.

Netflix raises its prices by 13% to 18% for U.S. subscribers. The immediate stock market price soars 6.5% as a result of this upward price adjustment. The b

+See More

With majority control, House Democrats pass 2 bills to reopen the U.S. government without funding the Trump border wall.

John Fourier

2019-01-12 10:33:00 Saturday ET

With majority control, House Democrats pass 2 bills to reopen the U.S. government without funding the Trump border wall.

With majority control, House Democrats pass 2 bills to reopen the U.S. government without funding the Trump border wall. President Trump makes a surprise Wh

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More